Severe adverse events · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…
1 finding from 1 review
Severe adverse events · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…
1 finding from 1 review
Severe adverse events
4 findings from 1 review
no estimate extracted
0 studies · 0 participants
GRADE not reported
no estimate extracted
0 studies · 0 participants
GRADE not reported
no estimate extracted
0 studies · 0 participants
GRADE not reported
Show 1 more finding
Adverse events (severe) · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events (severe) compared with stereotactic radiosurgery (very low certainty).
1 finding from 1 review
Severe/serious adverse events · women with locally advanced cervical cancer
Hysterectomy (simple or radical) with radiotherapy may leads to higher severe/serious adverse events compared with radiotherapy alone (low certainty).
1 finding from 1 review
Severe/serious adverse events · women with locally advanced cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Severe adverse events (≥ grade 3) · women withe low‐risk GTN
The intervention showed no clear difference in severe adverse events (≥ grade 3) (low certainty).
1 finding from 1 review
Severe adverse events and toxicity · women with locally advanced cervical cancer
Hysterectomy (simple or radical) with neoadjuvant chemotherapy showed no clear difference in severe adverse events and toxicity compared with radiotherapy alone (low certainty).
1 finding from 1 review
Overall severe adverse events (grade > 3) · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings 2: PLD alone changes overall severe adverse events (grade > 3) compared with other conventional chemotherapy (very low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy probably leads to higher overall severe adverse events (grade ≥ 3) compared with PLD alone (moderate certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
Summary of findings 1: PLD with chemotherapy showed no clear difference in overall severe adverse events (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi… changes any severe adverse events (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (very low certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ postoperative G3+ events (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Adverse events: severe adverse events requiring treatment discontinuation ‐ TMP/SMX versus placebo or no treatment Clinical and laboratory criteria and treatment discontinuations · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
TMP/SMX showed no clear difference in adverse events: severe adverse events requiring treatment… compared with placebo, no treatment or non‐PCP drug (moderate certainty).
1 finding from 1 review